{"id":586771,"date":"2022-02-15T20:04:01","date_gmt":"2022-02-15T20:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=586771"},"modified":"2022-02-15T20:04:01","modified_gmt":"2022-02-15T20:04:01","slug":"palmar-fibromatosis-market-epidemiology-segmentation-emerging-therapy-assessment-and-market-report-scope","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/palmar-fibromatosis-market-epidemiology-segmentation-emerging-therapy-assessment-and-market-report-scope_586771.html","title":{"rendered":"Palmar Fibromatosis Market, Epidemiology Segmentation, Emerging Therapy Assessment, and Market Report Scope"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1644916447.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Palmar Fibromatosis Market, Epidemiology Segmentation, Emerging Therapy Assessment, and Market Report Scope \" src=\"https:\/\/www.abnewswire.com\/uploads\/1644916447.jpeg\" alt=\"Palmar Fibromatosis Market, Epidemiology Segmentation, Emerging Therapy Assessment, and Market Report Scope \" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight added a report on &ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/palmar-fibromatosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Palmar Fibromatosis Market<\/strong><\/a>&ldquo;. It covers an overview, its causes, signs and symptoms, and therapies. Major players are involved in developing therapies for <strong>Palmar Fibromatosis<\/strong>. The launch of emerging therapies will significantly impact the <strong>Palmar Fibromatosis market.<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Palmar Fibromatosis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Palmar Fibromatosis, also known as Dupuytren disease or Dupuytren contracture, is a benign fibroproliferative disorder in which subcutaneous fibrous nodules arise within the palmar fascia of the hand, eventually forming cordlike attachments with the adjacent flexor tendons. One of the earliest classifications of Dupuytren&rsquo;s disease according to the histological appearance using optical microscopy described three stages: proliferative, involutional, and residual.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get Sample Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/palmar-fibromatosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/palmar-fibromatosis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key highlights of the Palmar Fibromatosis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Males are affected 3-4 times more often than females and the disease is more severe in men.<\/li>\n<li>According to DelveInsight&rsquo;s analysis, older male population are affected more as compared to older female population, in case of Palmar Fibromatosis\/Dupuytren Contracture.<\/li>\n<li>The most common first symptom that led patients to seek treatment was a hard bump (48%), followed by ropelike growth (12%), pit or dimpling (11%), and bent fingers (10%).<\/li>\n<li><strong>Palmar Fibromatosis companies <\/strong>such as Endo Pharmaceutical, 180 Life Sciences\/University of Oxford, and several others.<\/li>\n<li><strong>Palmar Fibromatosis therapies <\/strong>such as XIAFLEX (collagenase clostridium histolyticum), Adalimumab, and several others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Palmar Fibromatosis Risk Factors<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Diabetes<\/li>\n<li>Smoking<\/li>\n<li>High blood cholesterol levels<\/li>\n<li>Alcohol abuse &mdash; particularly where liver disease is also present<\/li>\n<li>Occupations involving exposure to repetitive vibration.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Palmar Fibromatosis Symptoms<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Painless lump or Nodule in the palm<\/li>\n<li>Tightness<\/li>\n<li>Tenderness<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/palmar-fibromatosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Palmar Fibromatosis Treatment<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">Currently, there are no treatments to stop Dupuytren&#8217;s from getting worse, leaving surgery as the only viable option as the disease progresses. Surgery is considered if a finger has lost 30&deg; of the metacarpophalangeal joint or any proximal interphalangeal joint extension. Surgery is not advocated in early Dupuytren disease except when it is associated with persistent pain, especially at night.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get an overview sample report @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/palmar-fibromatosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"> https:\/\/www.delveinsight.com\/sample-request\/palmar-fibromatosis-market <\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Palmar Fibromatosis Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalent Cases<\/li>\n<li>Gender-specific Cases<\/li>\n<li>Treated Cases<\/li>\n<li>Age-specific Cases<\/li>\n<li>Diagnosed Cases<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Palmar Fibromatosis Treatment Market<\/strong><\/p>\n<p style=\"text-align: justify;\">The treatment for Dupuytren&#8217;s contracture relies upon the seriousness or severity of the condition. All through Dupuytren&#8217;s disease, fibrous tissue in the palm thickens and tightens. This makes one or more fingers to progressively stiffen, bend, and lose flexibility. The objective of treatment is to lessen the symptoms and disability caused by the disease.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Palmar Fibromatosis Market Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">There is no known cure for Dupuytren&#8217;s contracture; however, surgery is intended to &#8220;set back the clock&#8221; by reducing the restricting effect of the cords by either disrupting or removing them. Unfortunately, the healing tissues will form with the same potential to develop cords in the future but the gains in hand function can still be substantial. The surgical procedures most commonly performed for Dupuytren&#8217;s contracture are Fasciotomy and Subtotal palmar fasciectomy. Splinting may be used after surgery for Dupuytren&#8217;s contracture to protect the surgical site; however, it is not known if it reduces the risk of recurrent contracture or tightening of the healing wound.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Palmar Fibromatosis Emerging Therapy Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There is a need for improvement in the treatments. Therefore, testing a new treatment or to look at different combinations of existing treatments is necessary. Palmar Fibromatosis\/Dupuytren Contracture is not comprehensively studied, therefore, the emerging landscape of this condition is not very robust. As per the secondary domain searches and exploring clinical trials site, it has been observed that very few trials had been registered for this indication. No recent development has been reported in this space except for 180 Life Sciences.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Palmar Fibromatosis Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increase in prevalent cases of Palmar Fibromatosis\/Dupuytren Contracture<\/li>\n<li>High demand of disease-specific novel treatment will act as a market driver<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Palmar Fibromatosis Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Lack of robust pipeline<\/li>\n<li>High expenses associated with cost Dupuytren&rsquo;s contracture surgery<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request Sample Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/palmar-fibromatosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/palmar-fibromatosis-market <\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Palmar Fibromatosis<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Palmar Fibromatosis<\/p>\n<p style=\"text-align: justify;\">4. Palmar Fibromatosis: Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Palmar Fibromatosis: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Palmar Fibromatosis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Palmar Fibromatosis&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Palmar Fibromatosis Treatment<\/p>\n<p style=\"text-align: justify;\">11. Palmar Fibromatosis&nbsp;Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Palmar Fibromatosis&nbsp;Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Palmar Fibromatosis: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Palmar Fibromatosis<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=palmar-fibromatosis-market-epidemiology-segmentation-emerging-therapy-assessment-and-market-report-scope\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=palmar-fibromatosis-market-epidemiology-segmentation-emerging-therapy-assessment-and-market-report-scope\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight added a report on &ldquo;Palmar Fibromatosis Market&ldquo;. It covers an overview, its causes, signs and symptoms, and therapies. Major players are involved in developing therapies for Palmar Fibromatosis. The launch of emerging therapies will significantly impact the Palmar Fibromatosis &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/palmar-fibromatosis-market-epidemiology-segmentation-emerging-therapy-assessment-and-market-report-scope_586771.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-586771","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/586771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=586771"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/586771\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=586771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=586771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=586771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}